Skip to content

Advertisement

Molecular Neurodegeneration

  • Review
  • Open Access

Alpha-synuclein and tau: teammates in neurodegeneration?

  • 1,
  • 1,
  • 1,
  • 1,
  • 1, 2 and
  • 1, 2Email author
Molecular Neurodegeneration20149:43

https://doi.org/10.1186/1750-1326-9-43

©  Moussaud et al.; licensee BioMed Central Ltd. 2014

Received: 3 April 2014

Accepted: 16 October 2014

Published: 29 October 2014

Abstract

The accumulation of α-synuclein aggregates is the hallmark of Parkinson’s disease, and more generally of synucleinopathies. The accumulation of tau aggregates however is classically found in the brains of patients with dementia, and this type of neuropathological feature specifically defines the tauopathies. Nevertheless, in numerous cases α-synuclein positive inclusions are also described in tauopathies and vice versa, suggesting a co-existence or crosstalk of these proteinopathies. Interestingly, α-synuclein and tau share striking common characteristics suggesting that they may work in concord. Tau and α-synuclein are both partially unfolded proteins that can form toxic oligomers and abnormal intracellular aggregates under pathological conditions. Furthermore, mutations in either are responsible for severe dominant familial neurodegeneration. Moreover, tau and α-synuclein appear to promote the fibrillization and solubility of each other in vitro and in vivo. This suggests that interactions between tau and α-synuclein form a deleterious feed-forward loop essential for the development and spreading of neurodegeneration. Here, we review the recent literature with respect to elucidating the possible links between α-synuclein and tau.

Keywords

  • Tau
  • MAPT
  • Synuclein
  • SNCA
  • Oligomers
  • Tangles
  • Synucleinopathy
  • Tauopathy
  • Parkinson’s disease
  • Alzheimer’s disease

Introduction

Age-related neurodegenerative disorders like Alzheimer’s disease (AD) and Parkinson’s disease (PD) take an overwhelming toll on individuals and society [1]. AD and PD are the two most frequent neurodegenerative diseases (http://www.who.org). To date, PD and AD remain incurable and only very limited palliative treatment options exist [2]. The etiology of PD and AD is not fully understood, but appears to involve a complex combination of environmental and genetic factors [3].

Interestingly, at the molecular level, protein misfolding, accumulation, aggregation and subsequently the formation of amyloid deposits are common features in many neurological disorders including AD and PD. Thus neurodegenerative diseases are sometimes referred to as proteinopathies [4]. The existence of a common mechanism suggests that neurodegenerative disorders likely share a common trigger and that the nature of the pathology is determined by the type of the aggregated protein and the localization of the cell affected (Figures 1, 2 and 3).
Figure 1
Figure 1

Overlap of proteinopathies. In numerous neurodegenerative disorders, amyloid deposits composed of α-synuclein protein (red circle), tau protein (blue circle) and Aβ peptide (yellow circle) are found. Histopathological classification of neurodegenerative diseases is based on the nature and localization of these deposits in the nervous system. The pathologies are not hermetically isolated categories but form a continuum and concomitance of αsyn and tau pathology is not rare. αSyn pathology (or synucleinopathy) is not restricted to PD but is a feature of several dementing disorders such as PDD, DLB, and frequently occurs in AD where it contributes to secondary symptoms. By contrast tauopathy is repeatedly observed in numerous disorders primarily classified as synucleinopathies and may contribute to clinical heterogeneity.

Figure 2
Figure 2

Schematic representation of tau and α-synuclein proteins. A- Alternative splicing of the N1, N1 + N2 and R2 regions (white) yields in 6 different tau isoforms referred to as 0N3R (=tau23 or tau-352), 0N4R (=tau24 or tau-383), 1N3R (=tau37 or tau-381), 1N4R (=tau46 or tau-412), 2N3R (=tau39 or tau-410) and 2N4R (=tau40 or tau-441). Tau has an acidic N-terminus and a tubulin binding region where the vast majority of the exonic (▽) and intronic (not depicted here) disease-associated mutations are found. B- αSyn is a 14.5 kDa protein divided into 3 major regions; the amphipathic N-terminus, the hydrophobic Non-Amyloid Component (NAC) domain, and the acidic C-terminus. Pathogenic missense mutations described to date (▽) are located in the N-terminal region, whereas most disease-related phosphorylation sites (▲) are localized to the C-terminal region of the protein.

Figure 3
Figure 3

Tau and α-synuclein pathologies. A to D- Histological sections from the amygdala of DLB patients immunostained with an antibody against phosphorylated tau (PHF-1, Abcam, #ab66275) (A and B) or an antibody against phosphorylated αsyn (pSyn#64, Wako, #015-25191) (C and D). Abnormal proteinaceous inclusions of phosphorylated tau protein, called neurofibrillary tangles (A and B, ), and of αsyn protein, called Lewy bodies and neurites (C and D, ) are often found in neurons of the amygdala in DLB patients.

PD is pathologically characterized by the presence of Lewy bodies in the subcortical regions of the brain, which are composed of aggregated and phosphorylated alpha-synuclein protein (αsyn) (Figures 2 and 3) [5]. Hence PD belongs to a cluster of neurodegenerative disorders called synucleinopathies, which also includes Parkinson’s disease with dementia (PDD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) [6, 7] (Figure 1). AD can be classified as a tauopathy (as well as an amyloidopathy); a class of disorders with intracellular inclusions composed of hyperphosphorylated and aggregated tau protein in the form of neurofibrillary tangles or Pick’s bodies (Figures 2 and 3) [8]. Tauopathies also include frontotemporal dementia with parkinsonism linked to tau mutations on chromosome 17 (FTDP-17 T), Pick’s disease (PiD), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) (Figure 1).

The concept of the existence of a continuum between pure synucleinopathies and tauopathies has emerged and is supported by clinical observations of a high comorbidity and overlap between neurodegenerative disorders (Figure 1), in particular between dementia and parkinsonism [9]. In this continuum theory, two proteins are central: tau and αsyn. Both form abnormal intracellular inclusions, and mutations in either are sufficient to cause neurodegeneration. Recently new data has emerged which suggests that αsyn and tau may interact, and that this interaction is essential for the development and spreading of neurodegeneration. In the present manuscript we discuss the recent data in line with this paradigm.

Co-occurrence of tauopathies and synucleinopathies

There are many exceptions to the classical view that αsyn and tau pathology are the hallmarks of PD and AD [10], the obvious being that incidental tauopathy or synucleinopathy is sometimes observed in asymptomatic patients [11–14]. Furthermore tauopathies and synucleinopathies are not restricted to pure AD and PD respectively, but rather encompass a variety of other disorders in which co-occurrence of tau and αsyn inclusions is frequent such as in PDD, DLB, Lewy body variant of AD (LBVAD), Guam-Parkinson-ALS dementia complex [15, 16] and even Down’s syndrome [17] (Figure 1). Additionally, there is considerable crosstalk and comorbidity between PD and AD. For instance, PD patients are at increased risk of developing dementia [10, 18–21] and more than half of AD patients have Lewy bodies at autopsy, particularly in the amygdala [17, 22–24], with the presence of Lewy bodies correlating with faster and more aggressive pathology [25]. In sporadic PD, neurofibrillary tangles have been repeatedly described over the past century [26–29] and synaptic-enriched fractions of AD, PD, and DLB brains have been shown to contain high levels of S396 phospho-tau and phospho-αsyn [30]. Interestingly, dementia and pronounced tau pathology have been described in familial cases of parkinsonism linked to αsyn gene (SNCA) mutations [31–34]. In addition, in other familial forms of parkinsonism linked to PARKIN or LRRK2 gene mutations, the inconsistent accumulation of tau, αsyn, neither, or both proteins has been observed [10, 35].

In PD and PDD cases with tauopathy, phospho-tau is restricted to striatal tissues and dopaminergic neurons [36, 37] and some studies even co-localized tau and αsyn in the same aggregates. For instance in PD and DLB cases, phospho-tau and αsyn were sometimes found together in neurofibrillary tangles, Lewy bodies and neurites [38, 39]. In one study using mass spectrometry, tau was found as a component of Lewy bodies in addition to tubulin and other cytoskeletal proteins [40]. However at the molecular level, αsyn and tau were shown to segregate into different fibrillar species within one single aggregate [38].

SNCA and MAPTin genetic studies

It is fascinating to observe that familial cases carrying mutations in the microtubule-associated protein tau (MAPT) or SNCA genes can phenotypically present with a combination of both parkinsonism and dementia. For instance, familial forms of parkinsonism due to αsyn pathogenic substitutions (A30P, E46K, H50Q, G51D or A53T) or due to the duplication or triplication of the wild-type (wt) SNCA gene commonly present with additional atypical clinical signs such as hallucinations, cognitive impairment, and dementia [32, 35, 41–47].

Mutations in the MAPT gene also cause a variety of neurodegenerative phenotypes including parkinsonism. Pathogenicity of MAPT splice-site and missense mutations such as G272V, N279K, P301L, V337M and R406W were first reported to cause FTDP-17 T in 1998 (Figure 2) [48–52] followed by the description of many other intronic and exonic mutations (for reviews [53–56]). While most of the mutations such as P301L and N279K primarily cause familial FTD [50, 57], other phenotypes such as CBD [58, 59], PSP [60] and variable extent of parkinsonism have been observed in some patients and families with MAPT mutations. Whereas the S305N mutation provokes FTD with minimal parkinsonism [61], the K369I mutation is responsible for L-DOPA sensitive parkinsonism [62] and the deltaN296 mutation is related to familial atypical PSP [63]. Surprisingly, even single MAPT mutations cause considerable phenotypic heterogeneity even within a single family, with a diverse combination of symptoms and age of onset [64]. This apparent randomization of the symptoms raises some questions about the exact role and specificity of tau in neurodegeneration and suggests that tau is a trigger for diverse neurodegenerative cascades. Interestingly, no consistent synuclein pathology has been reported in FTDP-17 T patients. The presence of tauopathy combined with the absence of Lewy bodies in FTDP-17 T and post-encephalitic parkinsonism cases suggests that tau alone is sufficient to provoke severe neurodegeneration leading to parkinsonism [65, 66]. However, the absence of macroscopic Lewy bodies does not exclude a role for αsyn in the form of discrete oligomers.

Recently, large-scale unbiased population-based genotyping studies have attempted to associate disease susceptibility with common genetic variants. For PD, genome-wide association studies have identified at least 24 loci so far [67]. Among them, regions encompassing the GAK, HLA-DRB5, SNCA, LRRK2 and MAPT genes were the most significant hits [68–70]. The observation that common genetic variation in the SNCA and MAPT loci associates with susceptibility to disease supports a role for these genes in not only rare familial cases but also in sporadic PD. Common genetic variations at the MAPT locus can on the whole be divided in two major haplogroups named H1 and H2 that arose due to an ancient ~900 kb chromosome inversion. In comparison to H1, the H2 haplotype has been shown to correlate with lower expression of tau protein and to have a protective effect in neurodegeneration [71]. The MAPT H1 haplotype is therefore considered a genetic risk factor for a myriad of neurodegenerative disorders, including both pure tauopathies (PSP [60] and CBD [72–74]) and synucleinopathies (PD [75], PDD [76, 77] and MSA [78]). However, the H1 haplotype is very polymorphic and the specific genetic variants that associate with risk for each disorder are still not clearly defined.

In DLB, although no significant association of the MAPT locus with disease susceptibility was found in a recent genome-wide association study [79], correlation between H1 haplotype and the degree of synuclein pathology in the brainstem was observed in a small neuropathological study [80]. The SNCA single nucleotide polymorphism (SNP) rs2572324 has been correlated with the extent of neocortical Lewy body and neurofibrillary pathology [81]. These observations indicate that tau and αsyn may influence their reciprocal aggregation and suggest that their interaction is a determining factor for the development of dementia and parkinsonism. Other genetic/epidemiological studies have also indirectly linked MAPT/tau with PD. For instance, a SNP located within the RIT2 gene, was recently nominated through a meta-analysis of genome-wide association studies. GTP-binding protein Rit2 binds to calmodulin 1 (phosphorylase kinase, delta), which also binds to both tau and αsyn [68]. Increased PD susceptibility was also associated with two SNPs in the GSK3β gene, an established tau kinase [82], although these results could not be confirmed in a subsequent study or within the genome-wide association efforts [83]. Interestingly some epidemiological studies have also tried to determine if there is an evidence of an epistatic interaction between genetic variation of the SNCA and MAPT loci. An additive or even multiplicative effect between polymorphisms in SNCA and MAPT would be expected if both genes interact within the same pathogenic pathway. One study did suggest a synergistic increase in the susceptibility of developing dementia in patients with PD when a SNCA risk allele was analyzed with MAPT H1/H2 inversion polymorphism [76]. Conversely, no synergistic effect for SNCA and MAPT (or LRRK2) polymorphisms were found to increase PD susceptibility in two other epidemiological studies [84, 85] and one meta-analysis [86].

Tau and α-synuclein in vivomodels

Toxin-based rodent models

Prior to the discovery of the genetic forms of disease, i.e. mutations of MAPT and SNCA, toxin-based rodent models characterized in vivo parkinsonism research. The discovery that dopaminergic mid-brain neurons are especially sensitive to oxidative stress inducers such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-hydroxydopamine (6-OHDA), rotenone, and paraquat resulted in the creation of toxin-based rodent models to study parkinsonian phenotype in vivo (for review [87]). Interestingly, some studies also reported the accumulation of hyperphosphorylated tau in rodents after the systemic delivery of rotenone, paraquat, and MPTP, but not maneb [88–90]. In rotenone treated rats, Hoglinger and colleagues described fibrillar structures composed of 15 nm straight filaments positive for phospho-tau, thioflavin S, nitrosamine, and ubiquitin [89]. Insoluble and phosphorylated tau has been described in mice treated with MPTP [88] and Duka and colleagues demonstrated that MPTP treatment induces tau hyperphosphorylation on the S396 and S404 residues via GSK3β kinase in wt but not in αsyn knock-out (KO) mice [91]. Later, Qureshi and Paudel confirmed that αsyn presence is required for the MPTP-induced phosphorylation of tau at S214, S262, S396 and S404 residues and identified GSK3β and PKA as the responsible kinases [92]. However, a connection between tauopathy and synucleinopathy has not been consistently observed in these PD toxin-based models. In an interesting study by Morris and colleagues, a reduction of tau expression did not prevent 6-OHDA neurotoxicity [93]. These apparently contradictory results demonstrate that the interplay between tau and αsyn is complex.

αSyn and tau viral overexpression in rodents

The effect of targeted human αsyn and tau protein expression has been investigated using viral vectors-based models. In these models, co-occurrence of tau and αsyn pathologies has also been observed. For instance, in rats, αsyn overexpression induced by stereotaxic injection of lentivirus increases phospho-tau levels [94]. On the contrary, rats transduced with tau and mutant P301L tau display an increase of αsyn and phospho-αsyn levels [95]. In another study using adeno-associated vectors for gene transfer into the substantia nigra of rats, overexpression of human wt and P301L tau, but not αsyn, provoked dopaminergic neurodegeneration, reduced striatal dopamine content, and motor deficit as measured by amphetamine-stimulated rotational behavior [96]. In this study behavioral dysfunction preceded the formation of neurofibrillary tangles suggesting that mature neurofibrillary tangles are not required for tau-induced disruption of dopaminergic transmission [96].

Tau and αsyn genetic mouse models

Numerous genetically modified mice that overexpress the human tau and/or αsyn proteins have been generated and are used to model specific aspects of the human diseases. Interestingly, tau transgenic models not only develop cognitive changes but also motor dysfunction. Mice overexpressing the mutant K369I tau develop L-DOPA sensitive parkinsonism [62], and overexpression of the pathogenic P301L and P301S forms of tau in mice provoke severe motor dysfunctions that recapitulate some of their effects in humans [97, 98]. In the P301L tau overexpressing mouse line, inhibition of tau hyperphosphorylation by treatment with a non-specific protein kinase inhibitor also prevents the motor impairments suggesting that tau could be a target in degenerative movement disorders [99].

Likewise, cognitive deficits and tauopathy have been observed in αsyn-overexpressing PD models [100–103]. Interestingly different extents of tauopathy and cognitive impairment were observed depending on the promoter type used for αsyn overexpression and the species of αsyn expressed. The presence of hyperphosphorylated tau was clearly identified in a wt αsyn overexpressing transgenic mouse line using the PDGF-β promoter at 11 months of age [101, 102]. Nonetheless, no tauopathy was observed at 18 months in a transgenic line overexpressing wt αsyn under the prion promoter unless this line was crossed with a P301L tau mouse [100]. Interestingly, in two other lines also using the prion promoter to overexpress the A53T and E46K mutant forms of αsyn, abundant tau inclusions were observed without the need of crossing with the P301L tau expressing line [100, 104, 105]. The E46K line was reported to have more tau threads than the A53T αsyn overexpressing transgenic line suggesting mutation-induced differences [104]. In these mice, tauopathy was restricted to areas with abundant αsyn expression and initiated simultaneously with synucleinopathy in an age-dependent fashion, although not always localized within the same cells [100]. In the PDGF-β-wt-αsyn mice, hyperphosphorylated tau was primarily found in the brainstem and in the striatum [101, 102]. Kaul and colleagues correlated phospho-tau occurrence with the activation of ERK and JNK but not of GSK3β and p38MAPK kinases, whereas Haggerty and colleagues noted a match between the presence of phospho-tau and phospho-GSK3β. Similarly, in the prion promoter driven A53T αsyn mice, as well as in patients harboring the A53T mutation, hyperphosphorylated and non-soluble tau accumulated in the striatum and was correlated with increased levels of phospho-GSK3β [105, 106]. In contrast, in a Thy-1 promoter driven A30P αsyn overexpressing transgenic mouse line, hyperphosphorylated and non-soluble tau accumulated in the brainstem in correlation with increased phospho-JNK level [107]. Jointly, these observations suggest the existence of complex region- and time-dependent interactions between kinases, αsyn and tau.

Some groups also crossed different transgenic mouse models to trigger the co-occurrence of tauopathy and synucleinopathy with the final aim to better model complex human disorders like DLB. For instance, a quadruple transgenic mouse line has been generated by crossing a triple transgenic mouse that overexpresses human AD-causing M146V presenilin-1, APP Swedish mutation, and the FTDP-17 T-causing P301L tau with a transgenic mouse that overexpresses human PD-causing A53T αsyn [108]. Co-overexpression of these pathogenic proteins had a strong synergistic effect on neurodegeneration, protein aggregation, and on cognitive and motor deficits. In contrast, crossing of a Thy1 promoter driven human wt αsyn overexpressing mouse line with a tau KO or tau conditional KO mouse did not prevent neurotoxicity indicating that αsyn also acts independently from tau [93].

Several tau- and αsyn- deficient mouse lines have been generated to determine if any particular phenotype or resistance to neurodegeneration might be present. Generally, tau- or αsyn-deficient mice are viable with only minor phenotypic differences [109–112]. Remarkably, cognitive alterations were observed in an α- and γ-synuclein double KO mouse line suggesting that both proteins have a compensatory role on cognition [103]. Conversely, in aged tau-deficient animals minor motor deficits were observed in correlation with an iron accumulation and loss of dopaminergic neurons in the substantia nigra[113], but could not be reproduced in a subsequent study [112]. Together these data demonstrate that the absence of both proteins does not appear to have observable significant impact, perhaps due to compensatory mechanisms, whereas their overexpression, in particular in their mutated forms, recapitulates some aspects of the human pathologies. This is in line with a gain of toxic function mechanism and validates therapeutic strategies aimed at clearing tau and/or αsyn for parkinsonism and/or dementia.

Non-vertebrate models

In addition to rodents, non-vertebrate αsyn and/or tau transgenic in vivo models have been developed. These models work surprisingly well and present many practical aspects [114, 115]. For example, in Caenorhabditis elegans, expression of the human αsyn or tau protein in neurons recapitulates key features of the human diseases such as motor deficits and neuronal and dendritic loss [116]. Human αsyn expression in Drosophila melanogaster also induces neurotoxicity as well as L-DOPA-sensitive motor deficits and formation of αsyn-positive fibrils [117]. Remarkably, whereas αsyn expression provokes the formation of Lewy body-like aggregates in D. melanogaster but not in C. elegans, tau expression conversely leads to the formation of insoluble inclusions in C. elegans but not in D. melanogaster[115, 116]. Nonetheless, both proteins are neurotoxic in both models demonstrating that the formation of protein aggregates is fundamentally unnecessary for toxicity. In line with this idea, dopaminergic neurons in αsyn expressing D. melanogaster were rescued without suppressing the presence of αsyn inclusions by co-expression of the Hsp70 chaperone [118]. More recently, co-expression of tau and αsyn in D. melanogaster has been shown to induce motor dysfunction, dopaminergic denervation, cytotoxicity, formation of abnormal ubiquitin positive inclusions, axonal transport disruption, and cytoskeletal and synaptic disorganization [119]. Tau affected dopaminergic cell count only when co-expressed with αsyn, demonstrating the existence of a synergistic deleterious effect between tau and αsyn once more. However, in contrast to what was observed in rodent models, the mechanism of toxicity in D. melanogaster was linked to severe cytoskeletal and axonal disorganization and subsequent synaptic alterations rather than αsyn–promoted tau hyperphosphorylation [119].

Interesting findings have also been made in yeast models. In Saccharomyces cerevisiae, overexpressing human tau does not induce significant toxicity [120, 121]. However, co-expression of tau with human αsyn leads to greater toxicity than αsyn expression alone, and also leads to the formation of insoluble hyperphosphorylated tau and αsyn aggregates. The synergistic deleterious effects were increased by expression of A53T αsyn or P301L tau instead of their wt forms [120, 122]. Finally, in these models, yeast orthologs of the cyclin-dependent kinase 5 and GSK3β kinases were shown to be involved in the phosphorylation of tau and in the αsyn plus tau induced-toxicity [120, 122].

In various transgenic or toxin-induced PD models ranging from mice to yeast, the existence of a deleterious and emulative action between tau and αsyn has been repetitively shown. This corroborates what has been observed in humans (see Co-occurrence of tauopathies and synucleinopathies and SNCA and MAPT in genetic studies sections) and reinforces the idea that the interplay between αsyn and tau are pivotal in the neurodegenerative process. Nonetheless, results from these in vivo models have to be interpreted with caution. For instance, there is no ortholog gene of the human SNCA in the fly, worm or yeast, whereas in rodents the endogenous wt αsyn carries the A53T mutation without deleterious effect [123, 124]. Moreover, in rodents, tau hyperphosphorylation can occur in instances of hibernation or starvation, making this pathological hallmark difficult to interpret [125, 126].

Tau and α-synuclein in molecular studies

The fact that αsyn and tau can physically interact with each other was demonstrated by Jensen and colleagues in 1999. In this pioneering study, tau protein from brain lysates was pulled down by αsyn affinity chromatography. The authors also noted a strong effect of ionic strength on the binding, indicating the implication of salt bridges in the interaction [127]. Moreover, in line with an interaction under physiological conditions, a binding IC50 value of 50pM was calculated between tau and αsyn using plasmon surface resonance and a radioactive binding assay [127]. At the cellular level, tau and αsyn were co-localized in the same cellular compartments and in particular in axons [127]. This was confirmed by Förster resonance energy transfer (FRET) in more recent studies [128, 129].

Docking sites and effects of mutations on tau – αsyn interactions

Several studies have tried to identify the exact regions and the critical amino acid residues by which tau and αsyn interact. Using protein fragmentation and recombinant peptides, Jensen and colleagues found that the interacting domains are localized to the C-terminus of αsyn (55 to 140) and the microtubule binding region of tau (192 to 383) [127]. Accordingly two subsequent studies found that the N-terminal (1 to 153) and C-terminal (352 to 441) fragments of tau do not interact with αsyn [129, 130]. The question of the role of phosphorylation and disease-related mutations in the tau and αsyn interaction has also been addressed and investigated in vitro. Phosphorylation of the serine 214 residue of tau was identified to increase αsyn binding [92]. In contrast, phospho-mimic/dead mutations at the serine 129 residue of αsyn had no effect [129]. No effect of A30P and A53T αsyn disease-related mutations was initially reported [127], but later in a study using FRET, the αsyn mutation A30P, but not the A53T and E46K, was shown to reduce association of αsyn with tau [129]. Conversely, in a third study using co-immunoprecipitation, αsyn mutations A30P, A53T, E46K but not E83P increased binding with tau [92], E83P being an artificial mutation in the NAC domain that blocks αsyn aggregation [131]. On the contrary, the P301L tau mutation was found to reduce interaction with αsyn [130]. Consequently the exact role of the disease-related mutations on tau and αsyn interaction still needs to be clarified especially since in vivo observations suggest that they may play a role.

Tau – αsyn – kinases

The promotion of tau hyperphosphorylation by αsyn has been demonstrated in several studies and could be a mechanism that explains how αsyn triggers tauopathy (Figure 4). An in vitro study showed that αsyn promotes tau phosphorylation at S262 and S356 residues via PKA [127]. Later, another tau kinase, GSK3β, was found to be recruited and activated in an αsyn-dependent manner and provoke tau hyperphosphorylation at T181, S396, and S404 residues [88, 91, 120, 132]. This effect seems to be the result of both an increase GSK3β kinase activity [91, 105] and the formation of a tripartite GSK3β-αsyn-tau complex with tau binding to the acidic C-terminus of αsyn, and GSK3β to the NAC and KTEGV domains of αsyn [132]. However, it has also been shown that similar to αsyn, β- and γ-synuclein can also induce GSK3β autophosphorylation and that β-synuclein could even promote tau phosphorylation, questioning the specificity of this mechanism and its physiological relevance [132]. Nonetheless other facts reinforce the idea of a link between GSK3β, tau and αsyn. For instance, in a cellular MPTP model, GSK3β inhibition with lithium or TDZD-8 was able to decrease tau phosphorylation but also αsyn accumulation and cell death [91]. However GSK3β is not the only kinase that links αsyn with hyperphosphorylated tau. Indeed, activation of ERK and JNK, that also phosphorylate tau at S396 and S404 residues, correlate with the presence of phospho-tau in αsyn overexpressing transgenic mouse models [102, 106, 107]. In addition, tau phosphorylation at S262 and S356 residues by PKA is exacerbated by αsyn in vitro[127]. Following this, PKA was identified as the responsible kinase for the αsyn-dependent phosphorylation of tau at S262 residue after MPTP treatment in cells [92]. Interestingly, PKA does not phosphorylate tau at S396 and S404 residues, whereas GSK3β does not phosphorylate tau at S262 residue suggesting that both kinases probably have an additive role in the induction of tauopathy by αsyn (Figure 4). Recently, tau has been identified as a putative substrate for the PD-related kinase LRRK2 [133, 134] and genetic correction of the PD-related LRRK2 G2019S mutation in human induced pluripotent stem cells resulted in a decreased tau and αsyn expression [135], linking tau once more to PD.
Figure 4
Figure 4

Putative pathways of deleterious tau and α-synuclein interactions. Interaction of tau and αsyn may promote pathogenesis via distinct mechanisms. 1. αSyn may block the normal interaction between tau and tubulin by directly binding to tau and tubulin and thereby interfering with tau physiological function. 2. αSyn could recruit kinases and promote the hyperphosphorylation of tau. 3. αSyn may also catalyze tau polymerization and trigger the formation of tau/αsyn co-oligomers. 4. Finally, αsyn oligomers or fibrils may seed tau fibrillization and thereby initiate and propagate tauopathy.

Tau – αsyn – tubulin

αSyn may trigger tauopathy through the destabilization of the tau-tubulin interaction, which results in both tau aggregation and cytoskeleton disorganization (Figure 4). Interestingly, the 14-3-3 protein that shares some homology with αsyn [136] has also been found to bind to tau and cause tubulin instability [137]. Tau binding to tubulin is reduced by both direct competition with αsyn and indirectly by αsyn-promoted tau hyperphosphorylation [127]. Nevertheless the overall role of αsyn on cytoskeleton modeling is difficult to interpret. Indeed, similar to tau, wt but not mutant αsyn is capable of binding to tubulin and promoting tubulin polymerization [138–140]. Overexpression of A30P, A53T, E46K but not E83P mutated αsyn has been shown to decrease microtubule stability and promote phosphorylation of tau at the S262 residue by PKA [92]. Involvement of αsyn in cytoskeleton stability was also demonstrated by the disruptive effect of treatment with microtubule-destabilizing agents such as colchicine, nocodazole and vinblastine on the tubulin-αsyn interaction [129, 141]. Interestingly it was recently shown that seeds of αsyn dose-dependently reduce tau-promoted microtubule assembly, whereas αsyn oligomers impair microtubule-kinesin interplay [142].

Co-aggregation and seeding

In the last few years, effort has been directed at unravelling the mechanisms by which neurodegeneration progresses in the brain. In PD and AD, neurodegeneration and protein aggregation overlap with each other and seem to follow a preset path giving the impression of spreading [3]. Moreover, the existence of a prion-like cell-to-cell propagation mechanism has been suggested by the unexpected post mortem observation that αsyn aggregates spread to healthy transplanted neurons in PD patients [143, 144]. Consistently, infection of healthy cells by a seeding mechanism similar to the self-templating activity of prions has been shown in vitro and in vivo using polymerized αsyn and tau [145–154]. Moreover, αsyn and tau have been shown to be excreted from cells via non-conventional mechanisms and are found in exosomes [155, 156].

In this perspective, a major difference between tau and αsyn is that αsyn is prone to self-aggregate, whereas tau cannot aggregate by itself and requires an inducing agent [157]. This has raised the question of whether αsyn could initiate tau aggregation; indeed, in 2003, Giasson and colleagues demonstrated that αsyn and tau promote each other’s aggregation in vitro. Whereas the six alternative spliced variants of tau were able to aggregate in the presence of full length wt αsyn, tau aggregation was neither promoted by the delta71-82 truncated form of αsyn, nor by β-synuclein, nor by amyloidogenic Aβ peptide [100]. These observations demonstrate that tau accelerates αsyn polymerization and that αsyn can act as an inducing agent of tau polymerization through its hydrophobic NAC region. Interestingly, mutant A53T αsyn was shown to have increased tau fibrillization properties in vitro when compared to wt αsyn [33]. Conversely, tau expression enhanced toxicity and secretion, and changed the pattern of αsyn aggregation by promoting the formation of smaller inclusions in cellular models [128].

Using the fluorescent intensity distribution analysis technique (FIDA), Nübling and colleagues have shown that tau and αsyn can form co-oligomers and that co-aggregation happens even at nanomolar concentrations but only in the presence of a cationic aggregation inducer such as Al3+ and Fe3+ or DMSO [158]. Moreover, tau phosphorylation by GSK3β strongly enhanced the formation of mixed oligomers [158]. However electron microscopy revealed that co-incubation of monomeric tau and αsyn mainly leads to the formation of homopolymeric fibrils [100]. This is consistent with the observations made in DLB cases [38] and suggests that αsyn and tau predominantly interact with each other at the monomeric and oligomeric stages. More recently, a series of studies tried to reproduce these in vitro findings in vivo by demonstrating that exogenous αsyn can be taken up by neurons and induce the formation of intracellular Lewy body-like structures [159, 160] and also hyperphosphorylated tau aggregates [151, 161]. For instance extracellular treatment with polymerized recombinant human αsyn induced the formation of insoluble phosphorylated tau in cellular models [104, 161]. Counterintuitively, wt αsyn fibrils were more efficient than E46K αsyn fibrils at cross-seeding tau [104].

Conclusions and future directions

The overlap and numerous similarities between synucleinopathies and tauopathies suggest that therapeutic strategies that target common processes of tau and αsyn aggregation could benefit patients across a spectrum of neurodegenerative disorders, and may be particularly relevant for the treatment of secondary symptoms such as cognitive impairment in PD or secondary parkinsonism in dementia. In the present review we have compiled data from the literature linking tau and αsyn. The repeated in vitro and in vivo observations that tau and αsyn interact highly suggest that αsyn and tau play as teammates, however how this interaction occurs and affects neurodegenerative processes is still not fully elucidated and several scenarios are possible (Figure 4).

αSyn was initially shown to bind to tau and interfere with the normal interaction between tau and tubulin [127]. The disruption of the normal physiological interaction between tau and tubulin for a pathological interaction between tau and αsyn could explain why αsyn and tau interaction seems to be deleterious. However, more recent data suggest that the role of tau and αsyn interaction on cytoskeleton modeling, axonal development and synaptic activity in neurons may be more complex as first thought [119, 140, 142]. Additional mechanisms, acting together in a vicious cycle, may explain how αsyn triggers tau aggregation and vice versa. Reciprocal promotion of phosphorylation is probably a key player, suggesting that kinases could be used as targets. GSK3β inhibition for instance was concomitantly able to decrease tau phosphorylation, αsyn accumulation and cell death in a cellular MPTP model [91]. In a P301L tau overexpressing mouse line, inhibition of tau hyperphosphorylation by treatment with a non-specific protein kinase inhibitor prevented motor impairments [99].

A mechanistic cross-seeding effect based on templating of a pathological β-sheet conformation is also highly suspected [151, 159–161]. Indeed, αsyn and tau can form co-oligomers that catalyze aggregation and finally lead to the formation of pure homofibrils [100, 158]. This resembles the prion self-propagation mechanism and this parallel is now commonly drawn in the literature, even if there is no evidence of human-to-human transmission for αsyn or tau [162, 163]. However, mutual misfolding is probably the first event that leads to αsyn and tau synergistic co-aggregation. The fact that αsyn has homology with the 14-3-3 co-chaperone protein, a known partner of tau and αsyn, and is able to substitute 14-3-3 co-chaperone activity on 14-3-3 targets supports this hypothesis [136, 137]. In this regard upregulation of chaperone proteins is another promising strategy that is presently being investigated to restore the normal conformation of αsyn and tau (Figure 4). Heat shock proteins (HSPs) increase the association of tau with microtubules and regulate tau degradation, ubiquitination and phosphorylation [164, 165]. Hsp70 preferentially binds to tau oligomers and restores anterograde fast axonal transport [166]. Our group has demonstrated that αsyn aggregation can be blocked by modulating different chaperones including Hsp27, Hsp70, Hsp90, torsinA and CHIP [167–175]. HSPs have been shown to positively act on αsyn or on tau independently, but they may also have a neuroprotective effect by restoring and regulating the normal interaction between both proteins [130, 132].

Observations suggest that αsyn being a trigger of tauopathy is more plausible than the opposite scenario. For instance, whereas the presence of tau only accelerated αsyn polymerization, co-incubation with αsyn was necessary to trigger tau aggregation in vitro[100]. Consistently, tau ablation failed to prevent neurotoxicity in the 6-OHDA or wt αsyn overexpressing mouse models [125]. Furthermore, pronounced tauopathy has been described in αsyn transgenic mice [100–102, 104, 105] and in PD patients harboring the A53T mutation [31, 33, 34], whereas no consistent αsyn pathology has been reported in tau transgenic mice or FTDP-17 T patients [66]. However, this is somewhat contradicted by the observation that αsyn pathology in AD is more pronounced than the tau pathology in PD [16, 22–24, 26–29, 37].

Nonetheless, even if some gray areas persist regarding the mechanisms and roles of the interaction between tau and αsyn, applications and future directions are already emerging. One future development is the identification of reliable biomarkers for efficient diagnosis of neurodegenerative disorders at the prodromal stage. In addition to other proteins, αsyn and tau are presently being developed as cerebrospinal fluid biomarkers for improved clinical diagnoses. Cerebrospinal fluid levels of Aβ, total and phospho-αsyn, and total and phospho-tau change differentially depending on the nature of the disease. Consequently, looking at the ratios between these proteins could enable clinicians to determine the risk of developing PD, AD, or a mixed disorder such as DLB and provide them the needed therapeutic window to start preventive and tailor-made treatments [176].

Abbreviations

AD: 

Alzheimer’s disease

ALS: 

Amyotrophic lateral sclerosis

αsyn: 

Alpha-synuclein protein

DLB: 

Dementia with Lewy bodies

CBD: 

Corticobasal degeneration

FRET: 

Förster resonance energy transfer

FTDP-17 T: 

Frontotemporal dementia with parkinsonism linked to tau mutations on chromosome 17

GSK3β: 

Glycogen synthase kinase 3 beta

Hsps: 

Heat shock proteins

JNK: 

c-Jun N-terminal kinases

KO: 

Knock-out

LRRK2: 

Leucine reach repeat kinase 2

MAPK: 

Mitogen-activated protein kinase

MAPT : 

Tau gene

MPTP: 

1-methyl-4-phenyl-1:2:3:6-tetrahydropyridine

MSA: 

Multiple system atrophy

PD: 

Parkinson’s disease

PDD: 

Parkinson’s disease with dementia

PiD: 

Pick’s disease

PKA: 

Protein kinase A

PSP: 

Progressive supranuclear palsy

SNCA : 

αsyn gene

SNP: 

Single nucleotide polymorphisms

wt: 

Wild-type.

Declarations

Acknowledgements

This work was supported by the Mayo Clinic and the NIH NS063963. OAR is partially supported by NINDS R01# NS078086 and Mayo Clinic Florida is a Morris K. Udall Parkinson's Disease Research Center of Excellence (NINDS P50 #NS072187). The authors would like to thank A.-M. Baine, A. Bradshaw, A. Bronnhuber, Dr. M. Gan, Dr. W. Springer, Dr. F. Fiesel, Dr. C. Labbé, Dr. P. M. Tacik , Dr. M. G. Plumot and Dr. K. F. Bieniek for passionate scientific discussions.

Authors’ Affiliations

(1)
Mayo Clinic Jacksonville, Jacksonville, USA
(2)
Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, USA

References

  1. Weintraub D, Comella CL, Horn S: Parkinson's disease–part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care. 2008, 14: S40-S48.PubMedGoogle Scholar
  2. Weintraub D, Comella CL, Horn S: Parkinson's disease–part 2: treatment of motor symptoms. Am J Manag Care. 2008, 14: S49-S58.PubMedGoogle Scholar
  3. Braak H, Rub U, Gai WP, Del Tredici K: Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003, 110: 517-536. 10.1007/s00702-002-0808-2.PubMedGoogle Scholar
  4. Jones DR, Moussaud S, McLean P: Targeting heat shock proteins to modulate alpha-synuclein toxicity. Ther Adv Neurol Disord. 2014, 7: 33-51. 10.1177/1756285613493469.PubMed CentralPubMedGoogle Scholar
  5. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: Alpha-synuclein in Lewy bodies. Nature. 1997, 388: 839-840. 10.1038/42166.PubMedGoogle Scholar
  6. Irizarry MC, Growdon W, Gomez-Isla T, Newell K, George JM, Clayton DF, Hyman BT: Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol. 1998, 57: 334-337. 10.1097/00005072-199804000-00005.PubMedGoogle Scholar
  7. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M: Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett. 1998, 251: 205-208. 10.1016/S0304-3940(98)00504-7.PubMedGoogle Scholar
  8. Brion JP, Couck AM, Passareiro E, Flament-Durand J: Neurofibrillary tangles of Alzheimer's disease: an immunohistochemical study. J Submicrosc Cytol. 1985, 17: 89-96.PubMedGoogle Scholar
  9. Irwin DJ, Lee VM, Trojanowski JQ: Parkinson's disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat Rev Neurosci. 2013, 14: 626-636. 10.1038/nrn3549.PubMed CentralPubMedGoogle Scholar
  10. Galpern WR, Lang AE: Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol. 2006, 59: 449-458. 10.1002/ana.20819.PubMedGoogle Scholar
  11. Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE: Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. 2008, 115: 437-444. 10.1007/s00401-008-0345-7.PubMedGoogle Scholar
  12. Evidente VG, Adler CH, Sabbagh MN, Connor DJ, Hentz JG, Caviness JN, Sue LI, Beach TG: Neuropathological findings of PSP in the elderly without clinical PSP: possible incidental PSP?. Parkinsonism Relat Disord. 2011, 17: 365-371. 10.1016/j.parkreldis.2011.02.017.PubMed CentralPubMedGoogle Scholar
  13. Mikolaenko I, Pletnikova O, Kawas CH, O'Brien R, Resnick SM, Crain B, Troncoso JC: Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol. 2005, 64: 156-162.PubMedGoogle Scholar
  14. Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, Arai T, Nagura H, Yamanouchi H, Hasegawa M, Iwatsubo T, Murayama S: Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol. 2003, 62: 644-654.PubMedGoogle Scholar
  15. Forman MS, Schmidt ML, Kasturi S, Perl DP, Lee VM, Trojanowski JQ: Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam. Am J Pathol. 2002, 160: 1725-1731. 10.1016/S0002-9440(10)61119-4.PubMed CentralPubMedGoogle Scholar
  16. Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, O'Connell B, Pollen DA, St George-Hyslop P, Ghetti B, Nochlin D, Bird TD, Cairns NJ, Lee VM, Iwatsubo T, Trojanowski JQ: Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol. 1998, 153: 1365-1370. 10.1016/S0002-9440(10)65722-7.PubMed CentralPubMedGoogle Scholar
  17. Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ: Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol. 1999, 45: 353-357. 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4.PubMedGoogle Scholar
  18. Aarsland D, Zaccai J, Brayne C: A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord. 2005, 20: 1255-1263. 10.1002/mds.20527.PubMedGoogle Scholar
  19. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA: Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology. 2005, 64: 1404-1410. 10.1212/01.WNL.0000158422.41380.82.PubMedGoogle Scholar
  20. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE: Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology. 2000, 54: 1916-1921. 10.1212/WNL.54.10.1916.PubMedGoogle Scholar
  21. Leverenz JB, Quinn JF, Zabetian C, Zhang J, Montine KS, Montine TJ: Cognitive impairment and dementia in patients with Parkinson disease. Curr Top Med Chem. 2009, 9: 903-912.PubMed CentralPubMedGoogle Scholar
  22. Hamilton RL: Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000, 10: 378-384.PubMedGoogle Scholar
  23. Leverenz JB, Fishel MA, Peskind ER, Montine TJ, Nochlin D, Steinbart E, Raskind MA, Schellenberg GD, Bird TD, Tsuang D: Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. Arch Neurol. 2006, 63: 370-376. 10.1001/archneur.63.3.370.PubMed CentralPubMedGoogle Scholar
  24. Leverenz JB, Hamilton R, Tsuang DW, Schantz A, Vavrek D, Larson EB, Kukull WA, Lopez O, Galasko D, Masliah E, Kaye J, Woltjer R, Clark C, Trojanowski JQ, Montine TJ: Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol. 2008, 18: 220-224. 10.1111/j.1750-3639.2007.00117.x.PubMed CentralPubMedGoogle Scholar
  25. Kraybill ML, Larson EB, Tsuang DW, Teri L, McCormick WC, Bowen JD, Kukull WA, Leverenz JB, Cherrier MM: Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology. 2005, 64: 2069-2073. 10.1212/01.WNL.0000165987.89198.65.PubMed CentralPubMedGoogle Scholar
  26. Bancher C, Braak H, Fischer P, Jellinger KA: Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci Lett. 1993, 162: 179-182. 10.1016/0304-3940(93)90590-H.PubMedGoogle Scholar
  27. Joachim CL, Morris JH, Kosik KS, Selkoe DJ: Tau antisera recognize neurofibrillary tangles in a range of neurodegenerative disorders. Ann Neurol. 1987, 22: 514-520. 10.1002/ana.410220411.PubMedGoogle Scholar
  28. Lewy FH: Paralysis agitans. Pathologische Anatomie Handbuch der Neurologie (Ed M Lewandowsky) Julius Springer. 1912, 3: 920-933.Google Scholar
  29. Schneider JA, Li JL, Li Y, Wilson RS, Kordower JH, Bennett DA: Substantia nigra tangles are related to gait impairment in older persons. Ann Neurol. 2006, 59: 166-173. 10.1002/ana.20723.PubMedGoogle Scholar
  30. Muntane G, Dalfo E, Martinez A, Ferrer I: Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Neuroscience. 2008, 152: 913-923. 10.1016/j.neuroscience.2008.01.030.PubMedGoogle Scholar
  31. Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, Lee VM, Trojanowski JQ: Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol. 2002, 104: 7-11. 10.1007/s00401-002-0563-3.PubMedGoogle Scholar
  32. Fujioka S, Ogaki K, Tacik PM, Uitti RJ, Ross OA, Wszolek ZK: Update on novel familial forms of Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord. 2014, 20 (Suppl 1): S29-S34.PubMed CentralPubMedGoogle Scholar
  33. Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, Trojanowski JQ, Lee VM: Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp Neurol. 2004, 187: 279-288. 10.1016/j.expneurol.2004.01.007.PubMedGoogle Scholar
  34. Yamaguchi K, Cochran EJ, Murrell JR, Polymeropoulos MH, Shannon KM, Crowther RA, Goedert M, Ghetti B: Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene. Acta Neuropathol. 2005, 110: 298-305. 10.1007/s00401-005-1042-4.PubMedGoogle Scholar
  35. Poulopoulos M, Levy OA, Alcalay RN: The neuropathology of genetic Parkinson's disease. Mov Disord. 2012, 27: 831-842. 10.1002/mds.24962.PubMed CentralPubMedGoogle Scholar
  36. Jellinger KA: Interaction between alpha-synuclein and tau in Parkinson's disease comment on Wills et al.: elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010; 225: 210-218. Exp Neurol. 2011, 227: 13-18. 10.1016/j.expneurol.2010.10.006.PubMedGoogle Scholar
  37. Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A: Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol. 2010, 225: 210-218. 10.1016/j.expneurol.2010.06.017.PubMed CentralPubMedGoogle Scholar
  38. Arima K, Mizutani T, Alim MA, Tonozuka-Uehara H, Izumiyama Y, Hirai S, Ueda K: NACP/alpha-synuclein and tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies. Acta Neuropathol. 2000, 100: 115-121. 10.1007/s004010050002.PubMedGoogle Scholar
  39. Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW: Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol. 2003, 62: 389-397.PubMedGoogle Scholar
  40. Leverenz JB, Umar I, Wang Q, Montine TJ, McMillan PJ, Tsuang DW, Jin J, Pan C, Shin J, Zhu D, Zhang J: Proteomic identification of novel proteins in cortical lewy bodies. Brain Pathol. 2007, 17: 139-145. 10.1111/j.1750-3639.2007.00048.x.PubMedGoogle Scholar
  41. Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, Weir D, Thompson C, Szu-Tu C, Trinh J, Aasly JO, Rajput A, Rajput AH, Jon Stoessl A, Farrer MJ: Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov Disord. 2013, 28: 811-813. 10.1002/mds.25421.PubMedGoogle Scholar
  42. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee A: Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004, 364: 1167-1169. 10.1016/S0140-6736(04)17103-1.PubMedGoogle Scholar
  43. Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P, Proukakis C, Quinn N, Lees AJ, Hardy J, Revesz T, Houlden H, Holton JL: alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?. Acta Neuropathol. 2013, 125: 753-769. 10.1007/s00401-013-1096-7.PubMed CentralPubMedGoogle Scholar
  44. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O: Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998, 18: 106-108. 10.1038/ng0298-106.PubMedGoogle Scholar
  45. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL: Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997, 276: 2045-2047. 10.1126/science.276.5321.2045.PubMedGoogle Scholar
  46. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K: alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003, 302: 841-10.1126/science.1090278.PubMedGoogle Scholar
  47. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG: The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004, 55: 164-173. 10.1002/ana.10795.PubMedGoogle Scholar
  48. Clark LN, Poorkaj P, Wszolek Z, Geschwind DH, Nasreddine ZS, Miller B, Li D, Payami H, Awert F, Markopoulou K, Andreadis A, D'Souza I, Lee VM, Reed L, Trojanowski JQ, Zhukareva V, Bird T, Schellenberg G, Wilhelmsen KC: Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci U S A. 1998, 95: 13103-13107. 10.1073/pnas.95.22.13103.PubMed CentralPubMedGoogle Scholar
  49. Dumanchin C, Camuzat A, Campion D, Verpillat P, Hannequin D, Dubois B, Saugier-Veber P, Martin C, Penet C, Charbonnier F, Agid Y, Frebourg T, Brice A: Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. Hum Mol Genet. 1998, 7: 1825-1829. 10.1093/hmg/7.11.1825.PubMedGoogle Scholar
  50. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, et al: Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998, 393: 702-705. 10.1038/31508.PubMedGoogle Scholar
  51. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg GD: Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998, 43: 815-825. 10.1002/ana.410430617.PubMedGoogle Scholar
  52. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B: Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A. 1998, 95: 7737-7741. 10.1073/pnas.95.13.7737.PubMed CentralPubMedGoogle Scholar
  53. D'Souza I, Schellenberg GD: Regulation of tau isoform expression and dementia. Biochim Biophys Acta. 2005, 1739: 104-115. 10.1016/j.bbadis.2004.08.009.PubMedGoogle Scholar
  54. Gendron TF, Petrucelli L: The role of tau in neurodegeneration. Mol Neurodegener. 2009, 4: 13-10.1186/1750-1326-4-13.PubMed CentralPubMedGoogle Scholar
  55. Liu F, Gong CX: Tau exon 10 alternative splicing and tauopathies. Mol Neurodegener. 2008, 3: 8-10.1186/1750-1326-3-8.PubMed CentralPubMedGoogle Scholar
  56. Spillantini MG, Goedert M: Tau pathology and neurodegeneration. Lancet Neurol. 2013, 12: 609-622. 10.1016/S1474-4422(13)70090-5.PubMedGoogle Scholar
  57. Arima K, Kowalska A, Hasegawa M, Mukoyama M, Watanabe R, Kawai M, Takahashi K, Iwatsubo T, Tabira T, Sunohara N: Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene. Neurology. 2000, 54: 1787-1795. 10.1212/WNL.54.9.1787.PubMedGoogle Scholar
  58. Di Maria E, Tabaton M, Vigo T, Abbruzzese G, Bellone E, Donati C, Frasson E, Marchese R, Montagna P, Munoz DG, Pramstaller PP, Zanusso G, Ajmar F, Mandich P: Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann Neurol. 2000, 47: 374-377. 10.1002/1531-8249(200003)47:3<374::AID-ANA15>3.0.CO;2-8.PubMedGoogle Scholar
  59. Kouri N, Carlomagno Y, Baker M, Liesinger AM, Caselli RJ, Wszolek ZK, Petrucelli L, Boeve BF, Parisi JE, Josephs KA, Uitti RJ, Ross OA, Graff-Radford NR, Deture MA, Dickson DW, Rademakers R: Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration. Acta Neuropathol. 2014, 127: 271-282. 10.1007/s00401-013-1193-7.PubMed CentralPubMedGoogle Scholar
  60. Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, Hardy J, Lynch T, Bigio E, Hutton M: Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet. 1999, 8: 711-715. 10.1093/hmg/8.4.711.PubMedGoogle Scholar
  61. Iijima M, Tabira T, Poorkaj P, Schellenberg GD, Trojanowski JQ, Lee VM, Schmidt ML, Takahashi K, Nabika T, Matsumoto T, Yamashita Y, Yoshioka S, Ishino H: A distinct familial presenile dementia with a novel missense mutation in the tau gene. Neuroreport. 1999, 10: 497-501. 10.1097/00001756-199902250-00010.PubMedGoogle Scholar
  62. Ittner LM, Fath T, Ke YD, Bi M, van Eersel J, Li KM, Gunning P, Gotz J: Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci U S A. 2008, 105: 15997-16002. 10.1073/pnas.0808084105.PubMed CentralPubMedGoogle Scholar
  63. Rossi G, Gasparoli E, Pasquali C, Di Fede G, Testa D, Albanese A, Bracco F, Tagliavini F: Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene. Ann Neurol. 2004, 55: 448-PubMedGoogle Scholar
  64. van Herpen E, Rosso SM, Serverijnen LA, Yoshida H, Breedveld G, van de Graaf R, Kamphorst W, Ravid R, Willemsen R, Dooijes D, Majoor-Krakauer D, Kros JM, Crowther RA, Goedert M, Heutink P, van Swieten JC: Variable phenotypic expression and extensive tau pathology in two families with the novel tau mutation L315R. Ann Neurol. 2003, 54: 573-581. 10.1002/ana.10721.PubMedGoogle Scholar
  65. Jellinger KA: Absence of alpha-synuclein pathology in postencephalitic parkinsonism. Acta Neuropathol. 2009, 118: 371-379. 10.1007/s00401-009-0537-9.PubMedGoogle Scholar
  66. Lee VM, Giasson BI, Trojanowski JQ: More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci. 2004, 27: 129-134. 10.1016/j.tins.2004.01.007.PubMedGoogle Scholar
  67. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, et al: Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet. 2014, 46: 989-993. 10.1038/ng.3043.PubMed CentralPubMedGoogle Scholar
  68. Labbe C, Ross OA: Association studies of sporadic Parkinson's disease in the genomic era. Curr Genomics. 2014, 15: 2-10. 10.2174/1389202914666131210212745.PubMed CentralPubMedGoogle Scholar
  69. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Kruger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonozi R, et al: Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009, 41: 1308-1312. 10.1038/ng.487.PubMed CentralPubMedGoogle Scholar
  70. Spencer CC, Plagnol V, Strange A, Gardner M, Paisan-Ruiz C, Band G, Barker RA, Bellenguez C, Bhatia K, Blackburn H, Blackwell JM, Bramon E, Brown MA, Burn D, Casas JP, Chinnery PF, Clarke CE, Corvin A, Craddock N, Deloukas P, Edkins S, Evans J, Freeman C, Gray E, Hardy J, Hudson G, Hunt S, Jankowski J, Langford C, Lees AJ, et al: Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet. 2011, 20: 345-353.PubMed CentralPubMedGoogle Scholar
  71. Wade-Martins R: Genetics: the MAPT locus-a genetic paradigm in disease susceptibility. Nat Rev Neurol. 2012, 8: 477-478. 10.1038/nrneurol.2012.169.PubMedGoogle Scholar
  72. Caffrey TM, Wade-Martins R: The role of MAPT sequence variation in mechanisms of disease susceptibility. Biochem Soc Trans. 2012, 40: 687-692. 10.1042/BST20120063.PubMedGoogle Scholar
  73. Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J, Lees AJ, Rossor MN, Quinn NP, Kertesz A, Khan MN, Hardy J, Lantos PL, St George-Hyslop P, Munoz DG, Mann D, Lang AE, Bergeron C, Bigio EH, Litvan I, Bhatia KP, Dickson D, Wood NW, Hutton M: Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology. 2001, 56: 1702-1706. 10.1212/WNL.56.12.1702.PubMedGoogle Scholar
  74. Pittman AM, Myers AJ, Abou-Sleiman P, Fung HC, Kaleem M, Marlowe L, Duckworth J, Leung D, Williams D, Kilford L, Thomas N, Morris CM, Dickson D, Wood NW, Hardy J, Lees AJ, de Silva R: Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet. 2005, 42: 837-846. 10.1136/jmg.2005.031377.PubMed CentralPubMedGoogle Scholar
  75. Zabetian CP, Hutter CM, Factor SA, Nutt JG, Higgins DS, Griffith A, Roberts JW, Leis BC, Kay DM, Yearout D, Montimurro JS, Edwards KL, Samii A, Payami H: Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Ann Neurol. 2007, 62: 137-144. 10.1002/ana.21157.PubMed CentralPubMedGoogle Scholar
  76. Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJ, Brown J, Ban M, Spillantini MG, Compston A, Burn DJ, Chinnery PF, Barker RA, Sawcer SJ: Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol. 2007, 62: 145-153. 10.1002/ana.21192.PubMedGoogle Scholar
  77. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA: The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009, 132: 2958-2969. 10.1093/brain/awp245.PubMedGoogle Scholar
  78. Vilarino-Guell C, Soto-Ortolaza AI, Rajput A, Mash DC, Papapetropoulos S, Pahwa R, Lyons KE, Uitti RJ, Wszolek ZK, Dickson DW, Farrer MJ, Ross OA: MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology. 2011, 76: 670-672. 10.1212/WNL.0b013e31820c30c1.PubMed CentralPubMedGoogle Scholar
  79. Bras J, Guerreiro R, Darwent L, Parkkinen L, Ansorge O, Escott-Price V, Hernandez DG, Nalls MA, Clark LN, Honig LS, Marder K, Van Der Flier WM, Lemstra A, Scheltens P, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Ortega-Cubero S, Pastor P, Ferman TJ, Graff-Radford NR, Ross OA, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, et al: Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet. 2014, ᅟ: ᅟ-in pressGoogle Scholar
  80. Colom-Cadena M, Gelpi E, Marti MJ, Charif S, Dols-Icardo O, Blesa R, Clarimon J, Lleo A: MAPT H1 haplotype is associated with enhanced alpha-synuclein deposition in dementia with Lewy bodies. Neurobiol Aging. 2013, 34: 936-942. 10.1016/j.neurobiolaging.2012.06.015.PubMedGoogle Scholar
  81. Peuralinna T, Oinas M, Polvikoski T, Paetau A, Sulkava R, Niinisto L, Kalimo H, Hernandez D, Hardy J, Singleton A, Tienari PJ, Myllykangas L: Neurofibrillary tau pathology modulated by genetic variation of alpha-synuclein. Ann Neurol. 2008, 64: 348-352. 10.1002/ana.21446.PubMedGoogle Scholar
  82. Kwok JB, Hallupp M, Loy CT, Chan DK, Woo J, Mellick GD, Buchanan DD, Silburn PA, Halliday GM, Schofield PR: GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol. 2005, 58: 829-839. 10.1002/ana.20691.PubMedGoogle Scholar
  83. Wider C, Vilarino-Guell C, Heckman MG, Jasinska-Myga B, Ortolaza-Soto AI, Diehl NN, Crook JE, Cobb SA, Bacon JA, Aasly JO, Gibson JM, Lynch T, Uitti RJ, Wszolek ZK, Farrer MJ, Ross OA: SNCA, MAPT, and GSK3B in Parkinson disease: a gene-gene interaction study. Eur J Neurol. 2011, 18: 876-881. 10.1111/j.1468-1331.2010.03297.x.PubMedGoogle Scholar
  84. Biernacka JM, Armasu SM, Cunningham JM, Ahlskog JE, Chung SJ, Maraganore DM: Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility?. Parkinsonism Relat Disord. 2011, 17: 730-736. 10.1016/j.parkreldis.2011.07.001.PubMedGoogle Scholar
  85. Mamah CE, Lesnick TG, Lincoln SJ, Strain KJ, de Andrade M, Bower JH, Ahlskog JE, Rocca WA, Farrer MJ, Maraganore DM: Interaction of alpha-synuclein and tau genotypes in Parkinson's disease. Ann Neurol. 2005, 57: 439-443. 10.1002/ana.20387.PubMedGoogle Scholar
  86. Elbaz A, Ross OA, Ioannidis JP, Soto-Ortolaza AI, Moisan F, Aasly J, Annesi G, Bozi M, Brighina L, Chartier-Harlin MC, Destee A, Ferrarese C, Ferraris A, Gibson JM, Gispert S, Hadjigeorgiou GM, Jasinska-Myga B, Klein C, Kruger R, Lambert JC, Lohmann K, van de Loo S, Loriot MA, Lynch T, Mellick GD, Mutez E, Nilsson C, Opala G, Puschmann A, Quattrone A, et al: Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann Neurol. 2011, 69: 778-792. 10.1002/ana.22321.PubMed CentralPubMedGoogle Scholar
  87. Bove J, Perier C: Neurotoxin-based models of Parkinson's disease. Neuroscience. 2012, 211: 51-76.PubMedGoogle Scholar
  88. Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, Goudreau JL, Sidhu A: Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. Faseb J. 2006, 20: 2302-2312. 10.1096/fj.06-6092com.PubMedGoogle Scholar
  89. Hoglinger GU, Lannuzel A, Khondiker ME, Michel PP, Duyckaerts C, Feger J, Champy P, Prigent A, Medja F, Lombes A, Oertel WH, Ruberg M, Hirsch EC: The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem. 2005, 95: 930-939. 10.1111/j.1471-4159.2005.03493.x.PubMedGoogle Scholar
  90. Wills J, Credle J, Oaks AW, Duka V, Lee JH, Jones J, Sidhu A: Paraquat, but not maneb, induces synucleinopathy and tauopathy in striata of mice through inhibition of proteasomal and autophagic pathways. PLoS One. 2012, 7: e30745-10.1371/journal.pone.0030745.PubMed CentralPubMedGoogle Scholar
  91. Duka T, Duka V, Joyce JN, Sidhu A: Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. Faseb J. 2009, 23: 2820-2830. 10.1096/fj.08-120410.PubMed CentralPubMedGoogle Scholar
  92. Qureshi HY, Paudel HK: Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro. J Biol Chem. 2011, 286: 5055-5068. 10.1074/jbc.M110.178905.PubMed CentralPubMedGoogle Scholar
  93. Morris M, Koyama A, Masliah E, Mucke L: Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease. PLoS One. 2011, 6: e29257-10.1371/journal.pone.0029257.PubMed CentralPubMedGoogle Scholar
  94. Khandelwal PJ, Dumanis SB, Feng LR, Maguire-Zeiss K, Rebeck G, Lashuel HA, Moussa CE: Parkinson-related parkin reduces alpha-Synuclein phosphorylation in a gene transfer model. Mol Neurodegener. 2010, 5: 47-10.1186/1750-1326-5-47.PubMed CentralPubMedGoogle Scholar
  95. Khandelwal PJ, Dumanis SB, Herman AM, Rebeck GW, Moussa CE: Wild type and P301L mutant Tau promote neuro-inflammation and alpha-Synuclein accumulation in lentiviral gene delivery models. Mol Cell Neurosci. 2012, 49: 44-53. 10.1016/j.mcn.2011.09.002.PubMed CentralPubMedGoogle Scholar
  96. Klein RL, Dayton RD, Lin WL, Dickson DW: Tau gene transfer, but not alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat. Neurobiol Dis. 2005, 20: 64-73. 10.1016/j.nbd.2005.02.001.PubMed CentralPubMedGoogle Scholar
  97. Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, Atzori C, Migheli A, Crowther RA, Ghetti B, Spillantini MG, Goedert M: Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. 2002, 22: 9340-9351.PubMedGoogle Scholar
  98. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M: Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000, 25: 402-405. 10.1038/78078.PubMedGoogle Scholar
  99. Le Corre S, Klafki HW, Plesnila N, Hubinger G, Obermeier A, Sahagun H, Monse B, Seneci P, Lewis J, Eriksen J, Zehr C, Yue M, McGowan E, Dickson DW, Hutton M, Roder HM: An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A. 2006, 103: 9673-9678. 10.1073/pnas.0602913103.PubMed CentralPubMedGoogle Scholar
  100. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM: Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. 2003, 300: 636-640. 10.1126/science.1082324.PubMedGoogle Scholar
  101. Haggerty T, Credle J, Rodriguez O, Wills J, Oaks AW, Masliah E, Sidhu A: Hyperphosphorylated Tau in an alpha-synuclein-overexpressing transgenic model of Parkinson's disease. Eur J Neurosci. 2011, 33: 1598-1610. 10.1111/j.1460-9568.2011.07660.x.PubMed CentralPubMedGoogle Scholar
  102. Kaul T, Credle J, Haggerty T, Oaks AW, Masliah E, Sidhu A: Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease. BMC Neurosci. 2011, 12: 79-10.1186/1471-2202-12-79.PubMed CentralPubMedGoogle Scholar
  103. Magen I, Chesselet MF: Mouse models of cognitive deficits due to alpha-synuclein pathology. J Parkinsons Dis. 2011, 1: 217-227.PubMedGoogle Scholar
  104. Emmer KL, Waxman EA, Covy JP, Giasson BI: E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J Biol Chem. 2011, 286: 35104-35118. 10.1074/jbc.M111.247965.PubMed CentralPubMedGoogle Scholar
  105. Wills J, Credle J, Haggerty T, Lee JH, Oaks AW, Sidhu A: Tauopathic changes in the striatum of A53T alpha-synuclein mutant mouse model of Parkinson's disease. PLoS One. 2011, 6: e17953-10.1371/journal.pone.0017953.PubMed CentralPubMedGoogle Scholar
  106. Oaks AW, Frankfurt M, Finkelstein DI, Sidhu A: Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function. PLoS One. 2013, 8: e60378-10.1371/journal.pone.0060378.PubMed CentralPubMedGoogle Scholar
  107. Frasier M, Walzer M, McCarthy L, Magnuson D, Lee JM, Haas C, Kahle P, Wolozin B: Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. Exp Neurol. 2005, 192: 274-287. 10.1016/j.expneurol.2004.07.016.PubMedGoogle Scholar
  108. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM: Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010, 30: 7281-7289. 10.1523/JNEUROSCI.0490-10.2010.PubMed CentralPubMedGoogle Scholar
  109. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A: Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000, 25: 239-252. 10.1016/S0896-6273(00)80886-7.PubMedGoogle Scholar
  110. Avila J, de Barreda EG, Fuster-Matanzo A, Simon D, Llorens-Martin M, Engel T, Lucas JJ, Diaz-Hernandez M, Hernandez F: Looking for novel functions of tau. Biochem Soc Trans. 2012, 40: 653-655. 10.1042/BST20120006.PubMedGoogle Scholar
  111. Harada A, Oguchi K, Okabe S, Kuno J, Terada S, Ohshima T, Sato-Yoshitake R, Takei Y, Noda T, Hirokawa N: Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature. 1994, 369: 488-491. 10.1038/369488a0.PubMedGoogle Scholar
  112. Morris M, Hamto P, Adame A, Devidze N, Masliah E, Mucke L: Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice. Neurobiol Aging. 2013, 34: 1523-1529. 10.1016/j.neurobiolaging.2012.12.003.PubMed CentralPubMedGoogle Scholar
  113. Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, Wong BX, Adlard PA, Cherny RA, Lam LQ, Roberts BR, Volitakis I, Egan GF, McLean CA, Cappai R, Duce JA, Bush AI: Tau deficiency induces Parkinsonism with dementia by impairing APP-mediated iron export. Nat Med. 2012, 18: 291-295. 10.1038/nm.2613.PubMedGoogle Scholar
  114. Dawson TM, Ko HS, Dawson VL: Genetic animal models of Parkinson's disease. Neuron. 2010, 66: 646-661. 10.1016/j.neuron.2010.04.034.PubMed CentralPubMedGoogle Scholar
  115. Prussing K, Voigt A, Schulz JB: Drosophila melanogaster as a model organism for Alzheimer's disease. Mol Neurodegener. 2013, 8: 35-10.1186/1750-1326-8-35.PubMed CentralPubMedGoogle Scholar
  116. Teschendorf D, Link CD: What have worm models told us about the mechanisms of neuronal dysfunction in human neurodegenerative diseases?. Mol Neurodegener. 2009, 4: 38-10.1186/1750-1326-4-38.PubMed CentralPubMedGoogle Scholar
  117. Feany MB, Bender WW: A Drosophila model of Parkinson's disease. Nature. 2000, 404: 394-398. 10.1038/35006074.PubMedGoogle Scholar
  118. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM: Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 2002, 295: 865-868. 10.1126/science.1067389.PubMedGoogle Scholar
  119. Roy B, Jackson GR: Interactions between Tau and alpha-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease. Hum Mol Genet. 2014, ᅟ: ᅟ-Google Scholar
  120. Ciaccioli G, Martins A, Rodrigues C, Vieira H, Calado P: A powerful yeast model to investigate the synergistic interaction of alpha-synuclein and tau in neurodegeneration. PLoS One. 2013, 8: e55848-10.1371/journal.pone.0055848.PubMed CentralPubMedGoogle Scholar
  121. Vandebroek T, Terwel D, Vanhelmont T, Gysemans M, Van Haesendonck C, Engelborghs Y, Winderickx J, Van Leuven F: Microtubule binding and clustering of human Tau-4R and Tau-P301L proteins isolated from yeast deficient in orthologues of glycogen synthase kinase-3beta or cdk5. J Biol Chem. 2006, 281: 25388-25397. 10.1074/jbc.M602792200.PubMedGoogle Scholar
  122. Zabrocki P, Pellens K, Vanhelmont T, Vandebroek T, Griffioen G, Wera S, Van Leuven F, Winderickx J: Characterization of alpha-synuclein aggregation and synergistic toxicity with protein tau in yeast. Febs J. 2005, 272: 1386-1400. 10.1111/j.1742-4658.2005.04571.x.PubMedGoogle Scholar
  123. Hamilton BA: alpha-Synuclein A53T substitution associated with Parkinson disease also marks the divergence of Old World and New World primates. Genomics. 2004, 83: 739-742. 10.1016/j.ygeno.2003.09.016.PubMedGoogle Scholar
  124. Larsen K, Hedegaard C, Bertelsen MF, Bendixen C: Threonine 53 in alpha-synuclein is conserved in long-living non-primate animals. Biochem Biophys Res Commun. 2009, 387: 602-605. 10.1016/j.bbrc.2009.07.070.PubMedGoogle Scholar
  125. Arendt T, Stieler J, Strijkstra AM, Hut RA, Rudiger J, Van der Zee EA, Harkany T, Holzer M, Hartig W: Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals. J Neurosci. 2003, 23: 6972-6981.PubMedGoogle Scholar
  126. Yanagisawa M, Planel E, Ishiguro K, Fujita SC: Starvation induces tau hyperphosphorylation in mouse brain: implications for Alzheimer's disease. FEBS Lett. 1999, 461: 329-333. 10.1016/S0014-5793(99)01480-5.PubMedGoogle Scholar
  127. Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, Jakes R: alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem. 1999, 274: 25481-25489. 10.1074/jbc.274.36.25481.PubMedGoogle Scholar
  128. Badiola N, de Oliveira RM, Herrera F, Guardia-Laguarta C, Goncalves SA, Pera M, Suarez-Calvet M, Clarimon J, Outeiro TF, Lleo A: Tau enhances alpha-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS One. 2011, 6: e26609-10.1371/journal.pone.0026609.PubMed CentralPubMedGoogle Scholar
  129. Esposito A, Dohm CP, Kermer P, Bahr M, Wouters FS: alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton. Neurobiol Dis. 2007, 26: 521-531. 10.1016/j.nbd.2007.01.014.PubMedGoogle Scholar
  130. Benussi L, Ghidoni R, Paterlini A, Nicosia F, Alberici AC, Signorini S, Barbiero L, Binetti G: Interaction between tau and alpha-synuclein proteins is impaired in the presence of P301L tau mutation. Exp Cell Res. 2005, 308: 78-84. 10.1016/j.yexcr.2005.04.021.PubMedGoogle Scholar
  131. Koo HJ, Lee HJ, Im H: Sequence determinants regulating fibrillation of human alpha-synuclein. Biochem Biophys Res Commun. 2008, 368: 772-778. 10.1016/j.bbrc.2008.01.140.PubMedGoogle Scholar
  132. Kawakami F, Suzuki M, Shimada N, Kagiya G, Ohta E, Tamura K, Maruyama H, Ichikawa T: Stimulatory effect of alpha-synuclein on the tau-phosphorylation by GSK-3beta. Febs J. 2011, 278: 4895-4904. 10.1111/j.1742-4658.2011.08389.x.PubMedGoogle Scholar
  133. Bailey RM, Covy JP, Melrose HL, Rousseau L, Watkinson R, Knight J, Miles S, Farrer MJ, Dickson DW, Giasson BI, Lewis J: LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. Acta Neuropathol. 2013, 126: 809-827. 10.1007/s00401-013-1188-4.PubMed CentralPubMedGoogle Scholar
  134. Kawakami F, Yabata T, Ohta E, Maekawa T, Shimada N, Suzuki M, Maruyama H, Ichikawa T, Obata F: LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One. 2012, 7: e30834-10.1371/journal.pone.0030834.PubMed CentralPubMedGoogle Scholar
  135. Reinhardt P, Schmid B, Burbulla LF, Schondorf DC, Wagner L, Glatza M, Hoing S, Hargus G, Heck SA, Dhingra A, Wu G, Muller S, Brockmann K, Kluba T, Maisel M, Kruger R, Berg D, Tsytsyura Y, Thiel CS, Psathaki OE, Klingauf J, Kuhlmann T, Klewin M, Muller H, Gasser T, Scholer HR, Sterneckert J: Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell. 2013, 12: 354-367. 10.1016/j.stem.2013.01.008.PubMedGoogle Scholar
  136. Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, Wolozin B: alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci. 1999, 19: 5782-5791.PubMedGoogle Scholar
  137. Hashiguchi M, Sobue K, Paudel HK: 14-3-3zeta is an effector of tau protein phosphorylation. J Biol Chem. 2000, 275: 25247-25254. 10.1074/jbc.M003738200.PubMedGoogle Scholar
  138. Alim MA, Hossain MS, Arima K, Takeda K, Izumiyama Y, Nakamura M, Kaji H, Shinoda T, Hisanaga S, Ueda K: Tubulin seeds alpha-synuclein fibril formation. J Biol Chem. 2002, 277: 2112-2117. 10.1074/jbc.M102981200.PubMedGoogle Scholar
  139. Alim MA, Ma QL, Takeda K, Aizawa T, Matsubara M, Nakamura M, Asada A, Saito T, Kaji H, Yoshii M, Hisanaga S, Ueda K: Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein. J Alzheimers Dis. 2004, 6: 435-442. discussion 443-439PubMedGoogle Scholar
  140. Zhou Y, Gu G, Goodlett DR, Zhang T, Pan C, Montine TJ, Montine KS, Aebersold RH, Zhang J: Analysis of alpha-synuclein-associated proteins by quantitative proteomics. J Biol Chem. 2004, 279: 39155-39164. 10.1074/jbc.M405456200.PubMedGoogle Scholar
  141. Wersinger C, Sidhu A: Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter. Biochemistry. 2005, 44: 13612-13624. 10.1021/bi050402p.PubMedGoogle Scholar
  142. Prots I, Veber V, Brey S, Campioni S, Buder K, Riek R, Bohm KJ, Winner B: alpha-Synuclein oligomers impair neuronal microtubule-kinesin interplay. J Biol Chem. 2013, 288: 21742-21754. 10.1074/jbc.M113.451815.PubMed CentralPubMedGoogle Scholar
  143. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW: Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008, 14: 504-506. 10.1038/nm1747.PubMedGoogle Scholar
  144. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, Widner H, Revesz T, Lindvall O, Brundin P: Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med. 2008, 14: 501-503. 10.1038/nm1746.PubMedGoogle Scholar
  145. Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, Probst A, Winkler DT, Reichwald J, Staufenbiel M, Ghetti B, Goedert M, Tolnay M: Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A. 2013, 110: 9535-9540. 10.1073/pnas.1301175110.PubMed CentralPubMedGoogle Scholar
  146. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M: Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009, 11: 909-913. 10.1038/ncb1901.PubMed CentralPubMedGoogle Scholar
  147. Clavaguera F, Hench J, Lavenir I, Schweighauser G, Frank S, Goedert M, Tolnay M: Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol. 2014, 127: 299-301. 10.1007/s00401-013-1231-5.PubMed CentralPubMedGoogle Scholar
  148. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M: Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci. 2007, 27: 9220-9232. 10.1523/JNEUROSCI.2617-07.2007.PubMedGoogle Scholar
  149. Danzer KM, Krebs SK, Wolff M, Birk G, Hengerer B: Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J Neurochem. 2009, 111: 192-203. 10.1111/j.1471-4159.2009.06324.x.PubMedGoogle Scholar
  150. Frost B, Jacks RL, Diamond MI: Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009, 284: 12845-12852. 10.1074/jbc.M808759200.PubMed CentralPubMedGoogle Scholar
  151. Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ, Lee VM: Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell. 2013, 154: 103-117. 10.1016/j.cell.2013.05.057.PubMedGoogle Scholar
  152. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM: Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci. 2013, 33: 1024-1037. 10.1523/JNEUROSCI.2642-12.2013.PubMed CentralPubMedGoogle Scholar
  153. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, Lee VM: Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011, 72: 57-71. 10.1016/j.neuron.2011.08.033.PubMed CentralPubMedGoogle Scholar
  154. Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, Gentleman SM, DeArmond SJ, Prusiner SB: Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci U S A. 2013, 110: 19555-19560. 10.1073/pnas.1318268110.PubMed CentralPubMedGoogle Scholar
  155. Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, Vanderburg CR, McLean PJ: Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 2012, 7: 42-10.1186/1750-1326-7-42.PubMed CentralPubMedGoogle Scholar
  156. Simon D, Garcia-Garcia E, Royo F, Falcon-Perez JM, Avila J: Proteostasis of tau: Tau overexpression results in its secretion via membrane vesicles. FEBS Lett. 2012, 586: 47-54. 10.1016/j.febslet.2011.11.022.PubMedGoogle Scholar
  157. Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA: Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature. 1996, 383: 550-553. 10.1038/383550a0.PubMedGoogle Scholar
  158. Nubling G, Bader B, Levin J, Hildebrandt J, Kretzschmar H, Giese A: Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with alpha-synuclein at the single molecule level. Mol Neurodegener. 2012, 7: 35-10.1186/1750-1326-7-35.PubMed CentralPubMedGoogle Scholar
  159. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM: Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012, 338: 949-953. 10.1126/science.1227157.PubMed CentralPubMedGoogle Scholar
  160. Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DM, Hasegawa M: Prion-like spreading of pathological alpha-synuclein in brain. Brain. 2013, 136: 1128-1138. 10.1093/brain/awt037.PubMed CentralPubMedGoogle Scholar
  161. Waxman EA, Giasson BI: Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci. 2011, 31: 7604-7618. 10.1523/JNEUROSCI.0297-11.2011.PubMed CentralPubMedGoogle Scholar
  162. Brown P, Gajdusek DC, Gibbs CJ, Asher DM: Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy. N Engl J Med. 1985, 313: 728-731. 10.1056/NEJM198509193131205.PubMedGoogle Scholar
  163. Irwin DJ, Abrams JY, Schonberger LB, Leschek EW, Mills JL, Lee VM, Trojanowski JQ: Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol. 2013, 70: 462-468. 10.1001/jamaneurol.2013.1933.PubMed CentralPubMedGoogle Scholar
  164. David DC, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini MG: Proteasomal degradation of tau protein. J Neurochem. 2002, 83: 176-185. 10.1046/j.1471-4159.2002.01137.x.PubMedGoogle Scholar
  165. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH, Browne SE, Hall A, Voellmy R, Tsuboi Y, Dawson TM, Wolozin B, Hardy J, Hutton M: CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet. 2004, 13: 703-714. 10.1093/hmg/ddh083.PubMedGoogle Scholar
  166. Patterson KR, Ward SM, Combs B, Voss K, Kanaan NM, Morfini G, Brady ST, Gamblin TC, Binder LI: Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport. Biochemistry. 2011, 50: 10300-10310. 10.1021/bi2009147.PubMed CentralPubMedGoogle Scholar
  167. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ: Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem. 2004, 279: 25497-25502. 10.1074/jbc.M400255200.PubMedGoogle Scholar
  168. McFarland NR, Dimant H, Kibuuka L, Ebrahimi-Fakhari D, Desjardins CA, Danzer KM, Danzer M, Fan Z, Schwarzschild MA, Hirst W, McLean PJ: Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not alpha-synuclein-induced neuronal cell loss. PLoS One. 2014, 9: e86048-10.1371/journal.pone.0086048.PubMed CentralPubMedGoogle Scholar
  169. McLean PJ, Kawamata H, Shariff S, Hewett J, Sharma N, Ueda K, Breakefield XO, Hyman BT: TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem. 2002, 83: 846-854. 10.1046/j.1471-4159.2002.01190.x.PubMedGoogle Scholar
  170. McLean PJ, Klucken J, Shin Y, Hyman BT: Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem Biophys Res Commun. 2004, 321: 665-669. 10.1016/j.bbrc.2004.07.021.PubMedGoogle Scholar
  171. Outeiro TF, Klucken J, Strathearn KE, Liu F, Nguyen P, Rochet JC, Hyman BT, McLean PJ: Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun. 2006, 351: 631-638. 10.1016/j.bbrc.2006.10.085.PubMed CentralPubMedGoogle Scholar
  172. Putcha P, Danzer KM, Kranich LR, Scott A, Silinski M, Mabbett S, Hicks CD, Veal JM, Steed PM, Hyman BT, McLean PJ: Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J Pharmacol Exp Ther. 2010, 332: 849-857. 10.1124/jpet.109.158436.PubMed CentralPubMedGoogle Scholar
  173. Sharma N, Hewett J, Ozelius LJ, Ramesh V, McLean PJ, Breakefield XO, Hyman BT: A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study. Am J Pathol. 2001, 159: 339-344. 10.1016/S0002-9440(10)61700-2.PubMed CentralPubMedGoogle Scholar
  174. Shin Y, Klucken J, Patterson C, Hyman BT, McLean PJ: The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem. 2005, 280: 23727-23734. 10.1074/jbc.M503326200.PubMedGoogle Scholar
  175. Tetzlaff JE, Putcha P, Outeiro TF, Ivanov A, Berezovska O, Hyman BT, McLean PJ: CHIP targets toxic alpha-Synuclein oligomers for degradation. J Biol Chem. 2008, 283: 17962-17968. 10.1074/jbc.M802283200.PubMed CentralPubMedGoogle Scholar
  176. Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O, Calabresi P: Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol. 2013, 9: 131-140. 10.1038/nrneurol.2013.10.PubMedGoogle Scholar

Copyright

© Moussaud et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement

Molecular Neurodegeneration

ISSN: 1750-1326